GD2BBDAP12 CAR-T

**GD2BBDAP12 CAR-T** is an investigational CAR-T cell therapy engineered to target GD2 (disialoganglioside GD2), a tumor-associated antigen overexpressed on neuroblastoma and certain solid tumors. It incorporates a DAP12 signaling domain, likely in a KIR/DAP12-based chimeric antigen receptor construct, which enhances T-cell activation and cytotoxicity compared to traditional CD3ζ-only CARs by recruiting DAP12 for improved signaling. Developed as a cellular immunotherapy, it is administered via intravenous infusion following lymphodepleting chemotherapy, showing potential in preclinical and early clinical settings for high-risk or relapsed/refractory GD2-positive cancers, with benefits including faster proliferation and reduced cytokine release syndrome severity.